Screening for Hypogonadism in Primary Healthcare: How to do this Effectively

被引:1
作者
Livingston, Mark [1 ]
Jones, Richard [2 ]
Hackett, Geoff [3 ]
Donnahey, Gemma [4 ]
Moreno, Gabriela Y. C. [5 ]
Duff, Christopher J. [6 ,7 ]
Heald, Adrian H. [8 ,9 ,10 ]
机构
[1] Walsall Manor Hosp, Dept Blood Sci, Walsall WS2 9PS, W Midlands, England
[2] Besins Healthcare UK Ltd, London, England
[3] Good Hope Hosp, Dept Urol, Sutton Coldfield, England
[4] EMIS Hlth, Leeds, W Yorkshire, England
[5] Projectos Estrategicos, Mexico City, DF, Mexico
[6] Univ Hosp North Midlands, Dept Clin Biochem, Stoke On Trent, Staffs, England
[7] Keele Univ, Inst Sci & Technol Med, Keele, Staffs, England
[8] Univ Manchester, Sch Med, Manchester, Lancs, England
[9] Univ Manchester, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England
[10] Salford Royal Hosp, Dept Endocrinol & Diabet, Salford, Lancs, England
关键词
testosterone; hypogonadism; body mass index; screening; disadvantage; TESTOSTERONE REPLACEMENT THERAPY; LATE-ONSET HYPOGONADISM; ANDROGEN DEFICIENCY; VISCERAL ADIPOSITY; METABOLIC SYNDROME; OLDER MEN; CARDIOVASCULAR-DISEASE; SERUM TESTOSTERONE; INSULIN-RESISTANCE; GLYCEMIC CONTROL;
D O I
10.1055/s-0043-114866
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Testosterone, the most important androgen produced by the testes, plays an integral role in male health. Testosterone levels are increasingly being checked in primary healthcare as awareness of the risks of male hypogonadism grows. Aim To investigate what tests are performed to screen for hypogonadism and to exclude secondary hypogonadism. Design and Setting All participants attended general practices in the UK. Methods Data search was performed using the EMIS (R) clinical database (provider of the majority of GP operating systems in Cheshire). The anonymised records of male patients aged 18-98 years who had undergone a check of serum testosterone during a 10-year period were analysed. Results Overall screening rate was 4.3 %. Of 8 788 men with a testosterone result, 1 924 men (21.9 %) had a total testosterone level < 10 nmol/L. Just 689 of 8 788 men (7.8 %) had a sex hormone-binding globulin (SHBG) result, corresponding to 30.5 % of those potentially hypogonadal. Estimated free testosterone was negatively associated with BMI (Spearman's rho-0.2, p < 0.001) as was total testosterone in the over 50 s. Of 1 924 potentially hypogonadal men with a serum testosterone < 10 nmol/L, 588 of 1 924 (30.6 %) had a check of serum prolactin. 46.3 % and 41.7 % had LH and FSH measured, respectively. Only 19.1 % of 1 924 men with a hypogonadal total testosterone level were subsequently put on testosterone replacement. The percentage of men in the relatively socially disadvantaged category was similar for both eugonadal and hypogonadal men with a much higher rate of screening for hypogonadism in more socially advantaged men. Conclusions Screening in primary healthcare identified a significant minority of men who had potential hypogonadism. Interpretation of a low serum testosterone requires measurement of serum prolactin, LH and FSH in order to rule out secondary hypogonadism. We suggest that this becomes part of routine screening with a balanced screening approach across the socioeconomic spectrum.
引用
收藏
页码:176 / 181
页数:6
相关论文
共 32 条
  • [1] Screening for hypogonadism in diabetes 2008/9: Results from the Cheshire Primary Care cohort
    Anderson, Simon George
    Heald, Adrian
    Younger, Novie
    Bujawansa, Sumudu
    Narayanan, Ram Prakash
    McCulloch, Alan
    Jones, Hugh
    [J]. PRIMARY CARE DIABETES, 2012, 6 (02) : 143 - 148
  • [2] [Anonymous], 1988, HLTH DEPRIVATION INE
  • [3] Prevalence and incidence of androgen deficiency in middle-aged and older men: Estimates from the Massachusetts Male Aging Study
    Araujo, AB
    O'Donnell, AB
    Brambilla, DJ
    Simpson, WB
    Longcope, C
    Matsumoto, AM
    McKinlay, JB
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (12) : 5920 - 5926
  • [4] Prevalence of symptomatic androgen deficiency in men
    Araujo, Andre B.
    Esche, Gretchen R.
    Kupelian, Varant
    O'Donnell, Amy B.
    Travison, Thomas G.
    Williams, Rachel E.
    Clark, Richard V.
    McKinlay, John B.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (11) : 4241 - 4247
  • [5] Predictive value of serum testosterone for type 2 diabetes risk assessment in men
    Atlantis, Evan
    Fahey, Paul
    Martin, Sean
    O'Loughlin, Peter
    Taylor, Anne W.
    Adams, Robert J.
    Shi, Zumin
    Wittert, Gary
    [J]. BMC ENDOCRINE DISORDERS, 2016, 16
  • [6] Testosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline
    Bhasin, Shalender
    Cunningham, Glenn R.
    Hayes, Frances J.
    Matsumoto, Alvin M.
    Snyder, Peter J.
    Swerdloff, Ronald S.
    Montori, Victor M.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (06) : 2536 - 2559
  • [7] Boyanov M A, 2003, Aging Male, V6, P1
  • [8] British Society for Sexual Medicine, 2010, GUID MAN SEX PROBL M
  • [9] Prevalence of hypothalamic-pituitary imaging abnormalities in impotent men with secondary hypogonadism
    Citron, JT
    Ettinger, B
    Rubinoff, H
    Ettinger, VM
    Minkoff, J
    Hom, F
    Kan, P
    Alloo, R
    [J]. JOURNAL OF UROLOGY, 1996, 155 (02) : 529 - 533
  • [10] Serum testosterone, testosterone replacement therapy and all-cause mortality in men with type 2 diabetes: retrospective consideration of the impact of PDE5 inhibitors and statins
    Hackett, G.
    Heald, A. H.
    Sinclair, A.
    Jones, P. W.
    Strange, R. C.
    Ramachandran, S.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2016, 70 (03) : 244 - 253